首页 > 最新文献

Cerebrovascular Diseases最新文献

英文 中文
Hair Follicle Mesenchymal Stem Cells Induce Neural Regeneration and Repair after Transient Ischemic Stroke. 毛囊间充质干细胞诱导短暂性脑卒中后神经再生和修复。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-21 DOI: 10.1159/000543261
Chen Yang, Lei Yu, Jia Wang, Xiaokun Wang, Yuhan Yang, Ni He, Shijing Zhang, Hao Tang, Chen Dan Zou

Aim: To investigate the effect of hair follicle mesenchymal stem cells (HFMSCs) in ischemic stroke. Materials & methods: Rat transient ischemic stroke model was established to verify the effect of HFMSC transplantation. Behavioral experiment and TTC staining were used to estimate neurological outcome after HFMSC therapy. Pathological experiments were used to investigate the therapeutic roles of HFMSCs.

Results: HFMSCs inhibited neural apoptosis and promoted neural proliferation. The number of neural cells around ischemic core increased after HFMSC transplantation. Besides, the grafted HFMSCs expressed neuron-specific marker in the penumbra. Finally, HFMSCs diminished infarct area and improved neurological scores.

Conclusion: HFMSCs can improve neurological outcome via anti-apoptosis and promoting neural stem cells proliferation, indicating their therapeutic potential in ischemic stroke.

目的:探讨毛囊间充质干细胞(HFMSCs)在缺血性脑卒中中的作用。材料,方法:建立大鼠短暂性脑卒中模型,验证HFMSC移植的效果。采用行为学实验和TTC染色评价HFMSC治疗后的神经系统预后。通过病理实验探讨HFMSCs的治疗作用。结果:HFMSCs抑制神经细胞凋亡,促进神经细胞增殖。骨髓间充质干细胞移植后,缺血核心周围的神经细胞数量增加。此外,移植的HFMSCs在半暗区表达神经元特异性标记物。最后,HFMSCs减少了梗死面积,提高了神经学评分。结论:HFMSCs可通过抗细胞凋亡和促进神经干细胞增殖改善神经系统预后,提示其在缺血性脑卒中中的治疗潜力。
{"title":"Hair Follicle Mesenchymal Stem Cells Induce Neural Regeneration and Repair after Transient Ischemic Stroke.","authors":"Chen Yang, Lei Yu, Jia Wang, Xiaokun Wang, Yuhan Yang, Ni He, Shijing Zhang, Hao Tang, Chen Dan Zou","doi":"10.1159/000543261","DOIUrl":"https://doi.org/10.1159/000543261","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the effect of hair follicle mesenchymal stem cells (HFMSCs) in ischemic stroke. Materials &amp; methods: Rat transient ischemic stroke model was established to verify the effect of HFMSC transplantation. Behavioral experiment and TTC staining were used to estimate neurological outcome after HFMSC therapy. Pathological experiments were used to investigate the therapeutic roles of HFMSCs.</p><p><strong>Results: </strong>HFMSCs inhibited neural apoptosis and promoted neural proliferation. The number of neural cells around ischemic core increased after HFMSC transplantation. Besides, the grafted HFMSCs expressed neuron-specific marker in the penumbra. Finally, HFMSCs diminished infarct area and improved neurological scores.</p><p><strong>Conclusion: </strong>HFMSCs can improve neurological outcome via anti-apoptosis and promoting neural stem cells proliferation, indicating their therapeutic potential in ischemic stroke.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"1-21"},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perfusion Image-Aided Treatment Decision for Acute Ischemic Stroke: Validation of a Clinical Decision Support System. 急性缺血性脑卒中的灌注图像辅助治疗决策:临床决策支持系统的验证。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-21 DOI: 10.1159/000543142
Xiang Li, Chao Wei, Yuefei Wu, Xiang Gao, Jie Sun, Tianqi Xu, Chushuang Chen, Qing Yang, Mark W Parsons, Yi Huang, Jianhong Yang, Longting Lin

Introduction: Our collaborative team has previously developed a prognostic model for acute ischemic stroke (AIS). This model, known as the clinical decision support system (CDSS), aims to provide personalized assistance to clinicians in making treatment decisions and improving patient prognosis. The objective of this study was to externally validate the model using Chinese AIS patients.

Methods: All enrolled patients arrived at the hospital within 24 h after stroke onset. The primary outcome was the likelihood of a favorable functional outcome, which was defined as a modified Rankin Scale (mRS) <2 at 90 days. The model's predictive performance was evaluated by assessing its discriminative power (area under the curve [AUC]) and calibration power (Hosmer-Lemeshow goodness-of-fit test, Brier score).

Results: In the validation cohort of 298 patients, the model demonstrated a moderate discriminatory ability to predict a favorable functional outcome (mRS 0-1), with an AUC of 0.805 (95% CI, 0.756-0.849). The calibration performance of the model was assessed using the Hosmer-Lemeshow chi-squared test, yielding a value of 9.211 and a p value of 0.325, and additionally, the Brier score for the prediction of a good outcome was 0.153, further supporting the model's good calibration performance.

Conclusion: The study introduces the CDSS that integrates clinical baseline data and imaging indicators of brain perfusion status. This CDSS provides clinicians with an intuitive risk assessment of different treatment strategies for AIS patients. Moreover, the CDSS highlights substantial variations in treatment outcomes among patients, suggesting that it has the potential to significantly enhance personalized treatment approaches.

我们的合作团队先前开发了急性缺血性卒中(AIS)的预后模型。该模型被称为临床决策支持系统(CDSS),旨在为临床医生提供个性化的治疗决策帮助,改善患者预后。本研究的目的是利用中国AIS患者对该模型进行外部验证。方法:所有入组患者均在卒中发作后24小时内到达医院。主要终点是功能预后良好的可能性,其定义为90天时修改的Rankin量表(mRS) < 2。通过评估模型的判别能力(曲线下面积,AUC)和校准能力(Hosmer-Lemeshow拟合优度检验,Brier评分)来评估模型的预测性能。结果:在298例患者的验证队列中,该模型在预测良好的功能预后(mRS 0-1)方面表现出中等的区分能力,AUC为0.805 (95% CI, 0.756-0.849)。采用Hosmer-Lemeshow卡方检验对模型的校准性能进行评估,结果为9.211,p值为0.325,预测结果良好的Brier评分为0.153,进一步支持模型具有良好的校准性能。结论:本研究引入了集临床基线数据和脑灌注状态影像学指标于一体的CDSS。该CDSS为临床医生提供了对AIS患者不同治疗策略的直观风险评估。此外,CDSS强调了患者治疗结果的实质性差异,表明它具有显著增强个性化治疗方法的潜力。
{"title":"Perfusion Image-Aided Treatment Decision for Acute Ischemic Stroke: Validation of a Clinical Decision Support System.","authors":"Xiang Li, Chao Wei, Yuefei Wu, Xiang Gao, Jie Sun, Tianqi Xu, Chushuang Chen, Qing Yang, Mark W Parsons, Yi Huang, Jianhong Yang, Longting Lin","doi":"10.1159/000543142","DOIUrl":"10.1159/000543142","url":null,"abstract":"<p><strong>Introduction: </strong>Our collaborative team has previously developed a prognostic model for acute ischemic stroke (AIS). This model, known as the clinical decision support system (CDSS), aims to provide personalized assistance to clinicians in making treatment decisions and improving patient prognosis. The objective of this study was to externally validate the model using Chinese AIS patients.</p><p><strong>Methods: </strong>All enrolled patients arrived at the hospital within 24 h after stroke onset. The primary outcome was the likelihood of a favorable functional outcome, which was defined as a modified Rankin Scale (mRS) <2 at 90 days. The model's predictive performance was evaluated by assessing its discriminative power (area under the curve [AUC]) and calibration power (Hosmer-Lemeshow goodness-of-fit test, Brier score).</p><p><strong>Results: </strong>In the validation cohort of 298 patients, the model demonstrated a moderate discriminatory ability to predict a favorable functional outcome (mRS 0-1), with an AUC of 0.805 (95% CI, 0.756-0.849). The calibration performance of the model was assessed using the Hosmer-Lemeshow chi-squared test, yielding a value of 9.211 and a p value of 0.325, and additionally, the Brier score for the prediction of a good outcome was 0.153, further supporting the model's good calibration performance.</p><p><strong>Conclusion: </strong>The study introduces the CDSS that integrates clinical baseline data and imaging indicators of brain perfusion status. This CDSS provides clinicians with an intuitive risk assessment of different treatment strategies for AIS patients. Moreover, the CDSS highlights substantial variations in treatment outcomes among patients, suggesting that it has the potential to significantly enhance personalized treatment approaches.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Right Bundle Branch Block with Ischemic Stroke Incidence: A UK Biobank Cohort Study. 右束支传导阻滞与缺血性卒中发生率的关联:英国生物库队列研究。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-14 DOI: 10.1159/000543258
Dougho Park, Sopheak Phoung, Phoeuk Borei, Myeonghwan Bang, Seungsoo Kim, Yousin Suh, Hyoung Seop Kim, Jong Hun Kim

Introduction: Right bundle branch block (RBBB) is often considered benign; however, its association with ischemic stroke (IS) remains unclear. We aimed to investigate the relationship between RBBB and the incidence of IS.

Methods: We conducted a retrospective cohort study using the UK Biobank database (2004-2021), which included 3,634 participants with new-onset RBBB and 3,643 matched controls. The primary outcome was the incidence of IS, while the secondary outcomes included atrial fibrillation (AF) and all-cause mortality. We applied a propensity score matching with variables such as age, sex, presence of hypertension, diabetes, dyslipidemia, and the Charlson Comorbidity Index. Subsequently, time-dependent Cox regression analyses were performed to assess the association between RBBB and the outcomes.

Results: The cumulative incidence of IS was higher in the RBBB group. RBBB was independently associated with an increased risk of IS (adjusted hazard ratio [aHR], 3.57; 95% confidence interval [CI], 2.12-6.03; p < 0.001), as well as AF (aHR, 4.58; 95% CI, 3.86-5.43; p < 0.001) and all-cause mortality (aHR, 2.66; 95% CI, 2.35-3.02; p < 0.001).

Conclusion: RBBB was associated with an increased risk of IS, independent of age, sex, and other comorbidities. These findings emphasize the need for careful monitoring and management of patients with RBBB to mitigate the risk of IS and other adverse outcomes. Further research is needed to elucidate the underlying mechanisms and better inform clinical management strategies for patients with RBBB.

右束分支阻滞(RBBB)通常被认为是良性的;然而,其与缺血性卒中(IS)的关系尚不清楚。我们的目的是探讨RBBB与IS发病率之间的关系。方法:我们使用英国生物银行数据库(2004-2021)进行了一项回顾性队列研究,其中包括3,634名新发RBBB患者和3,643名匹配对照。主要结局是IS的发生率,次要结局包括心房颤动(AF)和全因死亡率。我们应用了与年龄、性别、高血压、糖尿病、血脂异常和Charlson合并症指数等变量匹配的倾向评分。随后,进行了时间相关的Cox回归分析,以评估RBBB与结果之间的关系。结果:RBBB组IS累积发生率较高。RBBB与IS风险增加独立相关(调整风险比[aHR], 3.57;95%置信区间[CI], 2.12-6.03;p < 0.001),以及AF (aHR, 4.58;95% ci, 3.86-5.43;p < 0.001)和全因死亡率(aHR, 2.66;95% ci, 2.35-3.02;P < 0.001)。结论:RBBB与IS风险增加相关,与年龄、性别和其他合并症无关。这些发现强调需要仔细监测和管理RBBB患者,以减轻IS和其他不良后果的风险。需要进一步的研究来阐明潜在的机制,并更好地为RBBB患者的临床管理策略提供信息。
{"title":"Association of Right Bundle Branch Block with Ischemic Stroke Incidence: A UK Biobank Cohort Study.","authors":"Dougho Park, Sopheak Phoung, Phoeuk Borei, Myeonghwan Bang, Seungsoo Kim, Yousin Suh, Hyoung Seop Kim, Jong Hun Kim","doi":"10.1159/000543258","DOIUrl":"https://doi.org/10.1159/000543258","url":null,"abstract":"<p><strong>Introduction: </strong>Right bundle branch block (RBBB) is often considered benign; however, its association with ischemic stroke (IS) remains unclear. We aimed to investigate the relationship between RBBB and the incidence of IS.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the UK Biobank database (2004-2021), which included 3,634 participants with new-onset RBBB and 3,643 matched controls. The primary outcome was the incidence of IS, while the secondary outcomes included atrial fibrillation (AF) and all-cause mortality. We applied a propensity score matching with variables such as age, sex, presence of hypertension, diabetes, dyslipidemia, and the Charlson Comorbidity Index. Subsequently, time-dependent Cox regression analyses were performed to assess the association between RBBB and the outcomes.</p><p><strong>Results: </strong>The cumulative incidence of IS was higher in the RBBB group. RBBB was independently associated with an increased risk of IS (adjusted hazard ratio [aHR], 3.57; 95% confidence interval [CI], 2.12-6.03; p < 0.001), as well as AF (aHR, 4.58; 95% CI, 3.86-5.43; p < 0.001) and all-cause mortality (aHR, 2.66; 95% CI, 2.35-3.02; p < 0.001).</p><p><strong>Conclusion: </strong>RBBB was associated with an increased risk of IS, independent of age, sex, and other comorbidities. These findings emphasize the need for careful monitoring and management of patients with RBBB to mitigate the risk of IS and other adverse outcomes. Further research is needed to elucidate the underlying mechanisms and better inform clinical management strategies for patients with RBBB.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional Outcome Prediction in Japanese Patients with Nonsurgical Intracerebral Hemorrhage: The FSR ICH Score. 日本非手术脑出血患者的功能预后预测:FSR ICH评分。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-08 DOI: 10.1159/000543362
Takuya Kiyohara, Ryu Matsuo, Fumi Irie, Kuniyuki Nakamura, Jun Hata, Yoshinobu Wakisaka, Takanari Kitazono, Masahiro Kamouchi, Tetsuro Ago

Introduction: There has been limited research on predicting the functional prognosis of patients with nonsurgical intracerebral hemorrhage (ICH) from the acute stage. The aim of this study was to develop a risk prediction model for the natural course in patients with nonsurgical ICH and to evaluate its performance using a multicenter hospital-based prospective study of stroke patients in Japan.

Methods: We consecutively registered a total of 1,017 patients with acute ICH (mean age, 68 years) who underwent conservative treatment and followed them up for 3 months. The study outcome was a poor functional outcome (modified Rankin Scale score, 4-6) at 3 months after ICH onset. To develop the risk prediction model for natural course in patients with nonsurgical ICH, we included the following clinical common factors assessed on admission in daily clinical practice for ICH: age, sex, medical history (hypertension, diabetes mellitus, dyslipidemia, pre-stroke dementia, previous stroke, coronary artery disease, smoking status, alcohol drinking status, oral anticoagulation, and antiplatelet medication), admission status (time from onset to admission, systolic blood pressure, diastolic blood pressure, pulse pressure, plasma glucose levels, severity of the stroke), and neuroradiologic data (ICH location, intraventricular hemorrhage, and hematoma volume). The risk prediction model for poor functional outcome was developed using logistic regression analysis. In addition, the risk prediction model was translated into a point-based simple risk score (FSR ICH score) using the approach in the Framingham Heart Study.

Results: At 3 months after the ICH onset, 323 (31.8%) patients developed a poor functional outcome. Age, diabetes mellitus, pre-stroke dementia, NIHSS score on admission, intraventricular hemorrhage, and hematoma volume were included in the risk prediction model. This model demonstrated excellent discrimination (C statistic = 0.884 [95% confidence interval, 0.863-0.905]; optimism-corrected C statistic based on 200 bootstrap samples = 0.877) and calibration (Hosmer-Lemeshow goodness-of-fit test: p = 0.72). The FSR ICH score, a point-based simple risk score, also showed excellent discrimination, with a C statistic of 0.882 (95% CI: 0.861-0.903).

Conclusions: We developed a new risk prediction model for 3-month poor functional outcome in patients with nonsurgical ICH using a multicenter hospital-based prospective study in Japan. The current risk prediction model has the potential to be a useful tool for estimating the natural course in patients with nonsurgical ICH, aiding in making treatment decisions, including surgical options, early formulation of rehabilitation plans, and efficient utilization of medical resources.

导论:目前对非手术性脑出血(ICH)患者急性期功能预后的预测研究有限。本研究的目的是建立一种非手术脑出血患者自然病程的风险预测模型,并通过日本卒中患者的多中心医院前瞻性研究来评估其表现。方法:对1017例急性脑出血患者(平均年龄68岁)进行保守治疗,随访3个月。研究结果为脑出血发作后3个月的功能预后差(改良Rankin量表评分,4-6)。为了建立非手术脑出血患者自然病程的风险预测模型,我们在脑出血的日常临床实践中纳入了以下入院时评估的临床常见因素:年龄、性别、病史(高血压、糖尿病、血脂异常、卒中前痴呆、卒中史、冠状动脉疾病、吸烟、饮酒、口服抗凝、抗血小板药物)、入院情况(发病至入院时间、收缩压、舒张压、脉压、血糖水平、卒中严重程度)、神经影像学资料(脑出血部位、脑室内出血、血肿量)。采用logistic回归分析建立功能不良预后风险预测模型。此外,使用Framingham心脏研究中的方法将风险预测模型转化为基于点的简单风险评分(FSR ICH评分)。结果:脑出血发病3个月后,323例(31.8%)患者出现功能不良。风险预测模型包括年龄、糖尿病、卒中前痴呆、入院时NIHSS评分、脑室内出血和血肿体积。该模型具有很好的判别性(C统计量=0.884[95%置信区间,0.863-0.905];基于200个bootstrap样本的乐观校正C统计量=0.877)和校准(Hosmer-Lemeshow拟合优度检验:P=0.72)。FSR ICH评分,一种基于点的简单风险评分,也显示出很好的辨别能力,C统计量为0.882 (95% CI: 0.861-0.903)。结论:我们在日本开展了一项基于多中心医院的前瞻性研究,为非手术性脑出血患者3个月功能不良预后建立了一种新的风险预测模型。目前的风险预测模型有可能成为评估非手术脑出血患者自然病程的有用工具,有助于制定治疗决策,包括手术选择、早期制定康复计划和有效利用医疗资源。
{"title":"Functional Outcome Prediction in Japanese Patients with Nonsurgical Intracerebral Hemorrhage: The FSR ICH Score.","authors":"Takuya Kiyohara, Ryu Matsuo, Fumi Irie, Kuniyuki Nakamura, Jun Hata, Yoshinobu Wakisaka, Takanari Kitazono, Masahiro Kamouchi, Tetsuro Ago","doi":"10.1159/000543362","DOIUrl":"10.1159/000543362","url":null,"abstract":"<p><strong>Introduction: </strong>There has been limited research on predicting the functional prognosis of patients with nonsurgical intracerebral hemorrhage (ICH) from the acute stage. The aim of this study was to develop a risk prediction model for the natural course in patients with nonsurgical ICH and to evaluate its performance using a multicenter hospital-based prospective study of stroke patients in Japan.</p><p><strong>Methods: </strong>We consecutively registered a total of 1,017 patients with acute ICH (mean age, 68 years) who underwent conservative treatment and followed them up for 3 months. The study outcome was a poor functional outcome (modified Rankin Scale score, 4-6) at 3 months after ICH onset. To develop the risk prediction model for natural course in patients with nonsurgical ICH, we included the following clinical common factors assessed on admission in daily clinical practice for ICH: age, sex, medical history (hypertension, diabetes mellitus, dyslipidemia, pre-stroke dementia, previous stroke, coronary artery disease, smoking status, alcohol drinking status, oral anticoagulation, and antiplatelet medication), admission status (time from onset to admission, systolic blood pressure, diastolic blood pressure, pulse pressure, plasma glucose levels, severity of the stroke), and neuroradiologic data (ICH location, intraventricular hemorrhage, and hematoma volume). The risk prediction model for poor functional outcome was developed using logistic regression analysis. In addition, the risk prediction model was translated into a point-based simple risk score (FSR ICH score) using the approach in the Framingham Heart Study.</p><p><strong>Results: </strong>At 3 months after the ICH onset, 323 (31.8%) patients developed a poor functional outcome. Age, diabetes mellitus, pre-stroke dementia, NIHSS score on admission, intraventricular hemorrhage, and hematoma volume were included in the risk prediction model. This model demonstrated excellent discrimination (C statistic = 0.884 [95% confidence interval, 0.863-0.905]; optimism-corrected C statistic based on 200 bootstrap samples = 0.877) and calibration (Hosmer-Lemeshow goodness-of-fit test: p = 0.72). The FSR ICH score, a point-based simple risk score, also showed excellent discrimination, with a C statistic of 0.882 (95% CI: 0.861-0.903).</p><p><strong>Conclusions: </strong>We developed a new risk prediction model for 3-month poor functional outcome in patients with nonsurgical ICH using a multicenter hospital-based prospective study in Japan. The current risk prediction model has the potential to be a useful tool for estimating the natural course in patients with nonsurgical ICH, aiding in making treatment decisions, including surgical options, early formulation of rehabilitation plans, and efficient utilization of medical resources.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Music-Supported Therapy for Depression and Cognitive Disorders in People Living with Stroke and Its Impact on Quality of Life: A Systematic Evaluation and Meta-Analysis.
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-06 DOI: 10.1159/000543361
Zhen Wang, Yingxia Xue, Guiying Sun, Jiajia Yun, Yalei Li, Qi Chen, Ruiwen Wang, Jiahui Wang, Chao Ren

Introduction: Stroke not only leads to physical dysfunction in people living with stroke, but also causes emotional and cognitive abnormalities, which significantly affect survival and quality of life. Prior research has shown that music-supported therapy (MST) has the ability to improve depression and cognitive performance through stimulation of the central nervous system. Nevertheless, there is a dearth of rigorous systematic assessments of the effectiveness of MST in improving depression and cognitive impairments in people living with stroke, as well as the impact of these benefits on their overall quality of life. This systematic review and meta-analysis aimed to assess the impact of MST on emotional and cognitive impairments in people living with stroke, as well as its influence on their quality of life.

Methods: The PRISMA 2020 guidelines were followed to search for articles on MST treating depression and cognitive issues in people living with stroke in the PubMed, Embase, Web of Science, Wanfang, CNKI, CSTJ, and SinoMed databases, with a cut-off date of July 11, 2024. Two researchers utilized the revised Cochrane RoB-I risk of bias technique to evaluate the quality of all relevant literature obtained. They subsequently extracted and meta-analyzed the data using Review Manager 5.4.1 software.

Results: Seventy-two studies involving a total of 5,543 people living with stroke were included, and the meta-analysis revealed that MST had a significant effect on depression and cognitive deficits in people living with stroke (SMDHAMD = 1.49, 95% CI: 1.21-1.76, p < 0.001, MDMMSE = 2.53, CI: 1.60-3.45, p < 0.001, MDMoCA = 3.59, CI: 2.57-4.62, p < 0.001), which took effect from 2 weeks of treatment and was accompanied by an increase in serum 5-HT level (SMD5-HT = 2.22, CI: 1.47-2.96, p < 0.001) and improvements in depression and cognitive function, daily living abilities (SMDADL = 1.72, CI: 1.32-2.11, p < 0.001), limb motor function (SMDFMA = 1.25, CI: 0.47-2.02, p < 0.001), and neurological function (SMDNIHSS = -1.77, CI: -2.50 to -1.04, p < 0.001).

Conclusion: MST effectively improves depression and cognitive function of people living with a stroke and enhances their ability to perform daily activities and limb motor function. Importantly, improvements in depression and cognitive function occur earlier than those in daily life ability and neurological function. Additionally, the level of serum 5-HT may serve as a potential indicator for assessing the effectiveness of MST.

{"title":"Effects of Music-Supported Therapy for Depression and Cognitive Disorders in People Living with Stroke and Its Impact on Quality of Life: A Systematic Evaluation and Meta-Analysis.","authors":"Zhen Wang, Yingxia Xue, Guiying Sun, Jiajia Yun, Yalei Li, Qi Chen, Ruiwen Wang, Jiahui Wang, Chao Ren","doi":"10.1159/000543361","DOIUrl":"https://doi.org/10.1159/000543361","url":null,"abstract":"<p><strong>Introduction: </strong>Stroke not only leads to physical dysfunction in people living with stroke, but also causes emotional and cognitive abnormalities, which significantly affect survival and quality of life. Prior research has shown that music-supported therapy (MST) has the ability to improve depression and cognitive performance through stimulation of the central nervous system. Nevertheless, there is a dearth of rigorous systematic assessments of the effectiveness of MST in improving depression and cognitive impairments in people living with stroke, as well as the impact of these benefits on their overall quality of life. This systematic review and meta-analysis aimed to assess the impact of MST on emotional and cognitive impairments in people living with stroke, as well as its influence on their quality of life.</p><p><strong>Methods: </strong>The PRISMA 2020 guidelines were followed to search for articles on MST treating depression and cognitive issues in people living with stroke in the PubMed, Embase, Web of Science, Wanfang, CNKI, CSTJ, and SinoMed databases, with a cut-off date of July 11, 2024. Two researchers utilized the revised Cochrane RoB-I risk of bias technique to evaluate the quality of all relevant literature obtained. They subsequently extracted and meta-analyzed the data using Review Manager 5.4.1 software.</p><p><strong>Results: </strong>Seventy-two studies involving a total of 5,543 people living with stroke were included, and the meta-analysis revealed that MST had a significant effect on depression and cognitive deficits in people living with stroke (SMDHAMD = 1.49, 95% CI: 1.21-1.76, p < 0.001, MDMMSE = 2.53, CI: 1.60-3.45, p < 0.001, MDMoCA = 3.59, CI: 2.57-4.62, p < 0.001), which took effect from 2 weeks of treatment and was accompanied by an increase in serum 5-HT level (SMD5-HT = 2.22, CI: 1.47-2.96, p < 0.001) and improvements in depression and cognitive function, daily living abilities (SMDADL = 1.72, CI: 1.32-2.11, p < 0.001), limb motor function (SMDFMA = 1.25, CI: 0.47-2.02, p < 0.001), and neurological function (SMDNIHSS = -1.77, CI: -2.50 to -1.04, p < 0.001).</p><p><strong>Conclusion: </strong>MST effectively improves depression and cognitive function of people living with a stroke and enhances their ability to perform daily activities and limb motor function. Importantly, improvements in depression and cognitive function occur earlier than those in daily life ability and neurological function. Additionally, the level of serum 5-HT may serve as a potential indicator for assessing the effectiveness of MST.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"1-26"},"PeriodicalIF":2.2,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cerebral Artery Overexpression of the NMUR1 Gene Is Associated with Moyamoya Disease: A Weighted Gene Co-Expression Network Analysis. 大脑动脉NMUR1基因的过度表达与moyamoya病有关:加权基因共表达网络分析。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-02-24 DOI: 10.1159/000538035
Samuel D Pettersson, Shunsuke Koga, Shan Ali, Alejandro Enriquez-Marulanda, Philipp Taussky, Christopher S Ogilvy

Introduction: This study aimed to elucidate mechanisms underlying moyamoya disease (MMD) pathogenesis and to identify potential novel biomarkers. We utilized gene co-expression networks to identify hub genes associated with the disease.

Methods: Twenty-one middle cerebral artery (MCA) samples from MMD patients and 11 MCA control samples were obtained from the Gene Expression Omnibus (GEO) dataset, GSE189993. To discover functional pathways and potential biomarkers, weighted gene co-expression network analysis (WGCNA) was employed. The hub genes identified were re-assessed through differential gene expression analysis (DGEA) via DESeq2 for further reliability verification. Additional 4 samples from the superficial temporal arteries (STAs) from MMD patients were obtained from GSE141025, and a subgroup analysis stratified by arterial type (MCA vs. STA) DGEA was performed to assess if the hub genes associated with MMD are expressed significantly greater on the affected arteries compared to healthy ones in MMD.

Results: WGCNA revealed a predominant module encompassing 139 hub genes, predominantly associated with the neuroactive ligand-receptor interaction (NLRI) pathway. Of those, 17 genes were validated as significantly differentially expressed. Neuromedin U receptor 1 (NMUR1) and thyrotropin-releasing hormone were 2 out of the 17 hub genes involved in the NLRI pathway (log fold change [logFC]: 1.150, p = 0.00028; logFC: 1.146, p = 0.00115, respectively). MMD-only subgroup analysis stratified by location showed that NMUR1 is significantly overexpressed in the MCA compared to the STA (logFC: 1.962; p = 0.00053) which further suggests its possible localized involvement in the progressive stenosis seen in the cerebral arteries in MMD.

Conclusion: This is the first study to have performed WGCNA on samples directly affected by MMD. NMUR1 expression is well known to induce localized arterial smooth muscle constriction and, recently, type 2 inflammation which can predispose to arterial stenosis potentially advancing the symptoms and progression of MMD. Further validation and functional studies are necessary to understand the precise role of NMUR1 upregulation in MMD and its potential implications.

导言:本研究旨在阐明moyamoya病(MMD)的发病机制,并确定潜在的新型生物标志物。我们利用基因共表达网络来确定与该疾病相关的枢纽基因:从基因表达总库(Gene Expression Omnibus,GEO)数据集 GSE189993 中获得了 21 份 MMD 患者大脑中动脉(MCA)样本和 11 份 MCA 对照样本。为了发现功能通路和潜在的生物标记物,研究人员采用了加权基因共表达网络分析(WGCNA)。通过 DESeq2 的差异基因表达分析(DGEA)对确定的中心基因进行了重新评估,以进一步验证其可靠性。从 GSE141025 中获得了另外 4 份来自 MMD 患者颞浅动脉(STA)的样本,并按动脉类型(MCA 与 STA)进行了 DGEA 分层亚组分析,以评估与 MMD 相关的枢纽基因在 MMD 受影响动脉上的表达是否显著高于健康动脉:结果:WGCNA 揭示了一个包含 139 个枢纽基因的主要模块,这些基因主要与神经活性配体-受体相互作用(NLRI)通路有关。在这些基因中,有 17 个基因被证实有明显的差异表达。神经生长素 U 受体 1(NMUR1)和促甲状腺激素释放激素(TRH)是参与 NLRI 通路的 17 个中心基因中的 2 个(对数折叠变化 [logFC]:1.150,p = 0.00028;logFC:1.146,p = 0.00115)。按部位分层的仅MMD亚组分析显示,与STA相比,NMUR1在MCA中显著过表达(logFC:1.962;p = 0.00053),这进一步表明NMUR1可能局部参与了MMD患者脑动脉的进行性狭窄:这是首次对直接受 MMD 影响的样本进行 WGCNA 研究。众所周知,NMUR1 的表达会诱导局部动脉平滑肌收缩,最近还出现了 2 型炎症,这可能会导致动脉狭窄,并有可能加重 MMD 的症状和病情发展。要了解 NMUR1 上调在 MMD 中的确切作用及其潜在影响,还需要进一步的验证和功能研究。
{"title":"Cerebral Artery Overexpression of the NMUR1 Gene Is Associated with Moyamoya Disease: A Weighted Gene Co-Expression Network Analysis.","authors":"Samuel D Pettersson, Shunsuke Koga, Shan Ali, Alejandro Enriquez-Marulanda, Philipp Taussky, Christopher S Ogilvy","doi":"10.1159/000538035","DOIUrl":"10.1159/000538035","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to elucidate mechanisms underlying moyamoya disease (MMD) pathogenesis and to identify potential novel biomarkers. We utilized gene co-expression networks to identify hub genes associated with the disease.</p><p><strong>Methods: </strong>Twenty-one middle cerebral artery (MCA) samples from MMD patients and 11 MCA control samples were obtained from the Gene Expression Omnibus (GEO) dataset, GSE189993. To discover functional pathways and potential biomarkers, weighted gene co-expression network analysis (WGCNA) was employed. The hub genes identified were re-assessed through differential gene expression analysis (DGEA) via DESeq2 for further reliability verification. Additional 4 samples from the superficial temporal arteries (STAs) from MMD patients were obtained from GSE141025, and a subgroup analysis stratified by arterial type (MCA vs. STA) DGEA was performed to assess if the hub genes associated with MMD are expressed significantly greater on the affected arteries compared to healthy ones in MMD.</p><p><strong>Results: </strong>WGCNA revealed a predominant module encompassing 139 hub genes, predominantly associated with the neuroactive ligand-receptor interaction (NLRI) pathway. Of those, 17 genes were validated as significantly differentially expressed. Neuromedin U receptor 1 (NMUR1) and thyrotropin-releasing hormone were 2 out of the 17 hub genes involved in the NLRI pathway (log fold change [logFC]: 1.150, p = 0.00028; logFC: 1.146, p = 0.00115, respectively). MMD-only subgroup analysis stratified by location showed that NMUR1 is significantly overexpressed in the MCA compared to the STA (logFC: 1.962; p = 0.00053) which further suggests its possible localized involvement in the progressive stenosis seen in the cerebral arteries in MMD.</p><p><strong>Conclusion: </strong>This is the first study to have performed WGCNA on samples directly affected by MMD. NMUR1 expression is well known to induce localized arterial smooth muscle constriction and, recently, type 2 inflammation which can predispose to arterial stenosis potentially advancing the symptoms and progression of MMD. Further validation and functional studies are necessary to understand the precise role of NMUR1 upregulation in MMD and its potential implications.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Late Lesion Growth following Endovascular Therapy: Is 24 h Too Early to Assess Acute Infarct Size Including the Effects of Secondary Injury? 血管内治疗后的晚期病灶生长:24 小时内评估急性梗死面积(包括继发性损伤的影响)是否为时过早?
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-02-27 DOI: 10.1159/000536470
Marie Luby, Amie W Hsia, Carolyn A Lomahan, Victoria Uche, Rachel Davis, Yongwoo Kim, Sana Somani, Shannon Burton, Rainier Cabatbat, Veronica Craft, Jill B De Vis, Malik M Adil, Mariam M Afzal, Leila C Thomas, William Gandler, Evan S McCreedy, John K Lynch, Lawrence L Latour
<p><strong>Introduction: </strong>Stroke lesion volume on MRI or CT provides objective evidence of tissue injury as a consequence of ischemic stroke. Measurement of "final" lesion volume at 24-h following endovascular therapy (post-EVT) has been used in multiple studies as a surrogate for clinical outcome. However, despite successful recanalization, a significant proportion of patients do not experience favorable clinical outcome. The goals of this study were to quantify lesion growth during the first week after treatment, identify early predictors, and explore the association with clinical outcome.</p><p><strong>Methods: </strong>This is a prospective study of stroke patients at two centers who met the following criteria: (i) anterior large vessel occlusion acute ischemic stroke, (ii) attempted EVT, and (iii) had 3T MRI post-EVT at 24-h and 5-day. We defined "early" and "late" lesion growth as ≥10 mL lesion growth between baseline and 24-h diffusion-weighted imaging (DWI) and between 24-h DWI and 5-day fluid attenuated inversion recovery imaging, respectively. Complete reperfusion was defined as >90% reduction of the volume of tissue with perfusion delay (Tmax>6 s) between pre-EVT and 24-h post-EVT. Favorable clinical outcome was defined as modified Rankin scale (mRS) of 0-2 at 30 or 90 days.</p><p><strong>Results: </strong>One hundred twelve patients met study criteria with median age 67 years, 56% female, median admit NIHSS 19, 54% received IV or IA thrombolysis, 66% with M1 occlusion, and median baseline DWI volume 21.2 mL. Successful recanalization was achieved in 87%, and 68% had complete reperfusion, with an overall favorable clinical outcome rate of 53%. Nearly two-thirds (65%) of the patients did not have late lesion growth with a median volume change of -0.3 mL between 24-h and 5-day and an associated high rate of favorable clinical outcome (64%). However, ∼1/3 of patients (35%) did have significant late lesion growth despite successful recanalization (87%: 46% mTICI 2b/41% mTICI 3). Late lesion growth patients had a 27.4 mL change in late lesion volume and 30.1 mL change in early lesion volume. These patients had an increased hemorrhagic transformation (HT) rate of 68% with only 1 in 3 patients having favorable clinical outcome. Late lesion growth was independently associated with incomplete reperfusion, HT, and unfavorable outcome.</p><p><strong>Conclusion: </strong>Approximately 1 out of 3 patients had late lesion growth following EVT, with a favorable clinical outcome occurring in only 1 out of 3 of these patients. Most patients with no early lesion growth had no late lesion growth. Identification of patients with late lesion growth could be critical to guide clinical management and inform prognosis post-EVT. Additionally, it can serve as an imaging biomarker for the development of adjunctive therapies to mitigate reperfusion injury.</p><p><strong>Introduction: </strong>Stroke lesion volume on MRI or CT provides objective evidence o
导言 MRI 或 CT 上的卒中病灶体积提供了缺血性卒中导致组织损伤的客观证据。多项研究已将血管内治疗(EVT)后 24 小时的 "最终 "病灶体积测量作为临床预后的替代指标。然而,尽管血管再通术取得了成功,但仍有相当一部分患者的临床疗效并不理想。本研究的目的是量化治疗后第一周的病灶生长情况,确定早期预测因素,并探讨与临床预后的关系。方法 这是一项前瞻性研究,研究对象是两个中心符合以下标准的卒中患者:i)前方大血管闭塞(LVO)急性缺血性卒中;ii)尝试过 EVT;iii)EVT 后 24 小时和 5 天内进行过 3T MRI 检查。我们将 "早期 "和 "晚期 "病变增长分别定义为基线与 24 小时 DWI 之间以及 24 小时 DWI 与 5 天 FLAIR 之间病变增长≥10 毫升。完全再灌注的定义是:在EVT前和EVT后24小时之间,灌注延迟(Tmax>6秒)的组织体积减少>90%。30天或90天后的改良Rankin量表(mRS)为0-2,即为良好的临床结果。结果 112名患者符合研究标准,中位年龄67岁,56%为女性,中位NIHSS 19,54%接受了静脉或IA溶栓治疗,66%为M1闭塞,中位基线DWI体积21.2毫升。87%的患者成功再通,68%的患者完全再灌注,总体临床预后良好率为53%。近三分之二(65%)的患者没有出现晚期病变生长,24 小时至 5 天之间的中位体积变化为-0.3 毫升,相关的临床预后良好率也很高(64%)。然而,约有三分之一的患者(35%)尽管成功实现了再通畅,但其晚期病变仍有显著增长(87%:46% mTICI 2b/ 41% mTICI 3)。晚期病变增长患者的晚期病变体积变化为 27.4 毫升,早期病变体积变化为 30.1 毫升。这些患者的出血转化率增加了 68%,每 3 名患者中仅有 1 人的临床结果良好。晚期病灶增长与不完全再灌注、出血转化和不良预后密切相关。结论 EVT 术后,大约每 3 名患者中就有 1 人出现晚期病灶增生,其中每 3 名患者中只有 1 人的临床预后良好。大多数早期病灶没有生长的患者晚期病灶也没有生长。识别晚期病灶生长的患者对指导临床治疗和 EVT 后的预后至关重要。此外,它还可以作为一种成像生物标志物,用于开发减轻再灌注损伤的辅助疗法。
{"title":"Late Lesion Growth following Endovascular Therapy: Is 24 h Too Early to Assess Acute Infarct Size Including the Effects of Secondary Injury?","authors":"Marie Luby, Amie W Hsia, Carolyn A Lomahan, Victoria Uche, Rachel Davis, Yongwoo Kim, Sana Somani, Shannon Burton, Rainier Cabatbat, Veronica Craft, Jill B De Vis, Malik M Adil, Mariam M Afzal, Leila C Thomas, William Gandler, Evan S McCreedy, John K Lynch, Lawrence L Latour","doi":"10.1159/000536470","DOIUrl":"10.1159/000536470","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Stroke lesion volume on MRI or CT provides objective evidence of tissue injury as a consequence of ischemic stroke. Measurement of \"final\" lesion volume at 24-h following endovascular therapy (post-EVT) has been used in multiple studies as a surrogate for clinical outcome. However, despite successful recanalization, a significant proportion of patients do not experience favorable clinical outcome. The goals of this study were to quantify lesion growth during the first week after treatment, identify early predictors, and explore the association with clinical outcome.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This is a prospective study of stroke patients at two centers who met the following criteria: (i) anterior large vessel occlusion acute ischemic stroke, (ii) attempted EVT, and (iii) had 3T MRI post-EVT at 24-h and 5-day. We defined \"early\" and \"late\" lesion growth as ≥10 mL lesion growth between baseline and 24-h diffusion-weighted imaging (DWI) and between 24-h DWI and 5-day fluid attenuated inversion recovery imaging, respectively. Complete reperfusion was defined as &gt;90% reduction of the volume of tissue with perfusion delay (Tmax&gt;6 s) between pre-EVT and 24-h post-EVT. Favorable clinical outcome was defined as modified Rankin scale (mRS) of 0-2 at 30 or 90 days.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;One hundred twelve patients met study criteria with median age 67 years, 56% female, median admit NIHSS 19, 54% received IV or IA thrombolysis, 66% with M1 occlusion, and median baseline DWI volume 21.2 mL. Successful recanalization was achieved in 87%, and 68% had complete reperfusion, with an overall favorable clinical outcome rate of 53%. Nearly two-thirds (65%) of the patients did not have late lesion growth with a median volume change of -0.3 mL between 24-h and 5-day and an associated high rate of favorable clinical outcome (64%). However, ∼1/3 of patients (35%) did have significant late lesion growth despite successful recanalization (87%: 46% mTICI 2b/41% mTICI 3). Late lesion growth patients had a 27.4 mL change in late lesion volume and 30.1 mL change in early lesion volume. These patients had an increased hemorrhagic transformation (HT) rate of 68% with only 1 in 3 patients having favorable clinical outcome. Late lesion growth was independently associated with incomplete reperfusion, HT, and unfavorable outcome.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Approximately 1 out of 3 patients had late lesion growth following EVT, with a favorable clinical outcome occurring in only 1 out of 3 of these patients. Most patients with no early lesion growth had no late lesion growth. Identification of patients with late lesion growth could be critical to guide clinical management and inform prognosis post-EVT. Additionally, it can serve as an imaging biomarker for the development of adjunctive therapies to mitigate reperfusion injury.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Stroke lesion volume on MRI or CT provides objective evidence o","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"129-137"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex and Gender Publications in Brain Health: A Mapping Review of the Asia-Pacific Region. 脑健康方面的性别和性别出版物:亚太地区绘图审查。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-02-24 DOI: 10.1159/000537946
Megan Heffernan, Mark Woodward, Deidre Anne De Silva, Christopher Chen, Craig S Anderson, Christine Kremer, Katie Harris, Else Charlotte Sandset, Maria Teresa Ferretti, Valeria Caso, Cheryl Carcel

Introduction: Reporting of sex and gender analysis in medical research has been shown to improve quality of the science and ensure findings are applicable to women and men. There is conflicting evidence on whether efforts by funding agencies and medical journals to encourage reporting of sex and gender analysis have resulted in tangible improvements. This study mapped the inclusion of sex and gender analysis in stroke and dementia research conducted in the Asia-Pacific region.

Methods: A systematic search for Asia-Pacific stroke and dementia research was conducted in PubMed and papers included from the period 2012 to 2022. Eligible studies were reviewed for inclusion of a primary sex or gender focus and categorized by type of sex and gender analysis. Author gender was determined using an algorithm and its associations with inclusion of sex and gender analysis were examined.

Results: Total Asia-Pacific publications increased from 109 in 2012 to 313 in 2022, but the rate of studies with a primary sex or gender focus did not increase significantly (R2 = 0.06, F(1, 9) = 0.59, p = 0.46). Australia, China, India, Japan, and South Korea produced the most publications over the study period and were the only countries with at least 50 publications. The impact of author gender was mixed, with female first authorship associated with inclusion of sex or gender analysis and last female authorship associated with studies having a primary sex or gender focus.

Conclusions: In the Asia-Pacific, brain health research is currently centred around high-income countries, and efforts are needed to ensure research findings are applicable throughout the region. While there was a general increase in brain health publications over the last decade, the rate of sex and gender analysis was unchanged. This demonstrates that even with efforts in some countries in place, there is currently a lack of progress in the Asia-Pacific region to produce more research focussing on sex and gender analysis.

介绍:在医学研究中报告性别分析已被证明可以提高科学质量,并确保研究结果适用于女性和男性。关于资助机构和医学期刊为鼓励报告性与性别分析所做的努力是否带来了实实在在的改进,目前还存在相互矛盾的证据。本研究对亚太地区中风和痴呆研究中纳入性别分析的情况进行了摸底:方法:在 PubMed 上对亚太地区的脑卒中和痴呆症研究进行了系统搜索,并纳入了 2012 年至 2022 年期间的论文。对符合条件的研究进行了审查,以确定是否纳入了主要的性别或性别重点,并按性别和性别分析的类型进行了分类。使用算法确定作者性别,并研究其与纳入性别和性别分析的关联:亚太地区的论文总数从2012年的109篇增加到2022年的313篇,但主要关注性别或性别问题的研究比例并没有显著增加(R2 = 0.06,F(1,9) = 0.59,P = 0.46)。澳大利亚、中国、印度、日本和韩国在研究期间发表了最多的论文,也是唯一至少发表了 50 篇论文的国家。作者性别的影响参差不齐,女性为第一作者与纳入性别或性别分析有关,女性为最后作者与主要关注性别或性别问题的研究有关:在亚太地区,脑健康研究目前主要集中在高收入国家,因此需要努力确保研究成果适用于整个地区。虽然在过去十年中,脑健康出版物普遍增加,但性和性别分析的比例却没有变化。这表明,即使一些国家做出了努力,亚太地区目前在开展更多注重性和性别分析的研究方面仍缺乏进展。
{"title":"Sex and Gender Publications in Brain Health: A Mapping Review of the Asia-Pacific Region.","authors":"Megan Heffernan, Mark Woodward, Deidre Anne De Silva, Christopher Chen, Craig S Anderson, Christine Kremer, Katie Harris, Else Charlotte Sandset, Maria Teresa Ferretti, Valeria Caso, Cheryl Carcel","doi":"10.1159/000537946","DOIUrl":"10.1159/000537946","url":null,"abstract":"<p><strong>Introduction: </strong>Reporting of sex and gender analysis in medical research has been shown to improve quality of the science and ensure findings are applicable to women and men. There is conflicting evidence on whether efforts by funding agencies and medical journals to encourage reporting of sex and gender analysis have resulted in tangible improvements. This study mapped the inclusion of sex and gender analysis in stroke and dementia research conducted in the Asia-Pacific region.</p><p><strong>Methods: </strong>A systematic search for Asia-Pacific stroke and dementia research was conducted in PubMed and papers included from the period 2012 to 2022. Eligible studies were reviewed for inclusion of a primary sex or gender focus and categorized by type of sex and gender analysis. Author gender was determined using an algorithm and its associations with inclusion of sex and gender analysis were examined.</p><p><strong>Results: </strong>Total Asia-Pacific publications increased from 109 in 2012 to 313 in 2022, but the rate of studies with a primary sex or gender focus did not increase significantly (R2 = 0.06, F(1, 9) = 0.59, p = 0.46). Australia, China, India, Japan, and South Korea produced the most publications over the study period and were the only countries with at least 50 publications. The impact of author gender was mixed, with female first authorship associated with inclusion of sex or gender analysis and last female authorship associated with studies having a primary sex or gender focus.</p><p><strong>Conclusions: </strong>In the Asia-Pacific, brain health research is currently centred around high-income countries, and efforts are needed to ensure research findings are applicable throughout the region. While there was a general increase in brain health publications over the last decade, the rate of sex and gender analysis was unchanged. This demonstrates that even with efforts in some countries in place, there is currently a lack of progress in the Asia-Pacific region to produce more research focussing on sex and gender analysis.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"89-95"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcome of Mechanical Thrombectomy for Acute Basilar Artery Occlusion in Patients with Intracranial Atherosclerotic Disease. 颅内动脉粥样硬化症患者急性基底动脉闭塞的机械取栓术疗效。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-04-29 DOI: 10.1159/000539112
Huong Bich Thi Nguyen, Trung Quoc Nguyen, Vu Thanh Tran, Tra Son Vu Le, Anh Tuan Le Truong, Binh Nguyen Pham, Sang Hung Nguyen, Anit Kiran Behera, Thanh Thien Nguyen, Thang Ba Nguyen, Thanh N Nguyen, Thang Huy Nguyen

Introduction: Intracranial atherosclerotic disease (ICAD) has been identified as a major cause of acute basilar artery occlusion (BAO).This study compared the characteristics and treatment outcomes in acute BAO patients with and without ICAD.

Methods: A prospective cohort study was conducted at 115 People's Hospital, Ho Chi Minh city, Vietnam from August 2021 to June 2023. Patients with acute BAO who underwent endovascular treatment within 24 h from symptom onset were included (thrombectomy alone or bridging with intravenous alteplase). The baseline characteristics and outcomes were analyzed and compared between patients with and without ICAD. Good functional outcome was defined as mRS ≤3 at 90 days.

Results: Among the 208 patients enrolled, 112 (53.8%) patients were categorized in the ICAD group, and 96 (46.2%) in the non-ICAD group. Occlusion in the proximal segment of the basilar artery was more common in patients with ICAD (55.4% vs. 21.9%, p < 0.001), whereas the distal segment was the most common location in the non-ICAD group (58.3% vs. 10.7%, p < 0.001). Patients in the ICAD group were more likely to undergo treatment in the late window, with a higher mean onset-to-treatment time compared to the non-ICAD group (11.6 vs. 9.5 h, p = 0.01). In multivariable logistic regression analysis, distal segment BAO was negatively associated with ICAD (aOR 0.13, 95% CI: 0.05-0.32, p < 0.001), while dyslipidemia showed a positive association (aOR 2.44, 95% CI: 1.15-5.17, p = 0.02). There was a higher rate for rescue stenting in the ICAD compared to non-ICAD group (15.2% vs. 0%, p < 0.001). However, no significant differences were found between the two groups in terms of good outcome (45.5% vs. 44.8%, p = 0.91), symptomatic hemorrhage rates (4.5% vs. 8.3%, p = 0.25), and mortality (42% vs. 50%, p = 0.25).

Conclusion: ICAD was a common etiology in patients with BAO. The location segment of BAO and dyslipidemia were associated with ICAD in patients with BAO. There was no difference in 90-day outcomes between BAO patients with and without ICAD undergoing endovascular therapy.

引言 颅内动脉粥样硬化疾病(ICAD)已被确定为急性基底动脉闭塞(BAO)的主要病因。方法 一项前瞻性队列研究于 2021 年 8 月至 2023 年 6 月在越南胡志明市 115 人民医院进行。研究纳入了在症状出现后 24 小时内接受血管内治疗的急性 BAO 患者(单纯血栓切除术或与静脉注射阿替普酶桥接)。分析了基线特征和疗效,并对有 ICAD 和无 ICAD 的患者进行了比较。90天后mRS≤3为功能良好。结果 在入组的208名患者中,112人(53.8%)被归入ICAD组,96人(46.2%)被归入非ICAD组。基底动脉近段闭塞在 ICAD 患者中更为常见(55.4% vs 21.9%,p < 0.001),而远段闭塞在非 ICAD 组中最为常见(58.3% vs 10.7%,p < 0.001)。ICAD 组患者更有可能在晚期窗口期接受治疗,与非 ICAD 组患者相比,ICAD 组患者从发病到接受治疗的平均时间更长(11.6 小时 vs. 9.5 小时,P=0.01)。在多变量逻辑回归分析中,远段基底动脉闭塞与ICAD呈负相关(aOR 0.13,95% CI 0.05 - 0.32,p <0.001),而血脂异常呈正相关(aOR 2.44,95% CI 1.15 - 5.17,p = 0.02)。与非ICAD组相比,ICAD组的支架抢救率更高(15.2% vs. 0%,p <0.001)。然而,两组患者在良好预后(45.5% 对 44.8%,p = 0.91)、无症状出血率(4.5% 对 8.3%,p = 0.25)和死亡率(42% 对 50%,p = 0.25)方面无明显差异。结论 ICAD 是 BAO 患者的常见病因。基底动脉闭塞的位置段和血脂异常与 BAO 患者的 ICAD 相关。接受血管内治疗的 BAO 患者中有 ICAD 和没有 ICAD 的 90 天预后没有差异。
{"title":"Outcome of Mechanical Thrombectomy for Acute Basilar Artery Occlusion in Patients with Intracranial Atherosclerotic Disease.","authors":"Huong Bich Thi Nguyen, Trung Quoc Nguyen, Vu Thanh Tran, Tra Son Vu Le, Anh Tuan Le Truong, Binh Nguyen Pham, Sang Hung Nguyen, Anit Kiran Behera, Thanh Thien Nguyen, Thang Ba Nguyen, Thanh N Nguyen, Thang Huy Nguyen","doi":"10.1159/000539112","DOIUrl":"10.1159/000539112","url":null,"abstract":"<p><strong>Introduction: </strong>Intracranial atherosclerotic disease (ICAD) has been identified as a major cause of acute basilar artery occlusion (BAO).This study compared the characteristics and treatment outcomes in acute BAO patients with and without ICAD.</p><p><strong>Methods: </strong>A prospective cohort study was conducted at 115 People's Hospital, Ho Chi Minh city, Vietnam from August 2021 to June 2023. Patients with acute BAO who underwent endovascular treatment within 24 h from symptom onset were included (thrombectomy alone or bridging with intravenous alteplase). The baseline characteristics and outcomes were analyzed and compared between patients with and without ICAD. Good functional outcome was defined as mRS ≤3 at 90 days.</p><p><strong>Results: </strong>Among the 208 patients enrolled, 112 (53.8%) patients were categorized in the ICAD group, and 96 (46.2%) in the non-ICAD group. Occlusion in the proximal segment of the basilar artery was more common in patients with ICAD (55.4% vs. 21.9%, p < 0.001), whereas the distal segment was the most common location in the non-ICAD group (58.3% vs. 10.7%, p < 0.001). Patients in the ICAD group were more likely to undergo treatment in the late window, with a higher mean onset-to-treatment time compared to the non-ICAD group (11.6 vs. 9.5 h, p = 0.01). In multivariable logistic regression analysis, distal segment BAO was negatively associated with ICAD (aOR 0.13, 95% CI: 0.05-0.32, p < 0.001), while dyslipidemia showed a positive association (aOR 2.44, 95% CI: 1.15-5.17, p = 0.02). There was a higher rate for rescue stenting in the ICAD compared to non-ICAD group (15.2% vs. 0%, p < 0.001). However, no significant differences were found between the two groups in terms of good outcome (45.5% vs. 44.8%, p = 0.91), symptomatic hemorrhage rates (4.5% vs. 8.3%, p = 0.25), and mortality (42% vs. 50%, p = 0.25).</p><p><strong>Conclusion: </strong>ICAD was a common etiology in patients with BAO. The location segment of BAO and dyslipidemia were associated with ICAD in patients with BAO. There was no difference in 90-day outcomes between BAO patients with and without ICAD undergoing endovascular therapy.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"30-41"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140851512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Relation between Vascular Risk Factors and Flow in Cerebral Perforating Arteries: A 7 Tesla MRI Study. 血管风险因素与脑穿孔动脉血流之间的关系。7 特斯拉核磁共振成像研究。
IF 2.2 3区 医学 Q3 CLINICAL NEUROLOGY Pub Date : 2025-01-01 Epub Date: 2024-02-09 DOI: 10.1159/000537709
Laurien Onkenhout, Tine Arts, Doeschka Ferro, Sanne Kuipers, Eline Oudeman, Thijs van Harten, Matthias J P van Osch, Jaco Zwanenburg, Jeroen Hendrikse, Geert Jan Biessels, L Jaap Kappelle

Introduction: Cerebral perforating arteries provide blood supply to the deep regions of the brain. Recently, it became possible to measure blood flow velocity and pulsatility in these small arteries. It is unknown if vascular risk factors are related to these measures.

Methods: We measured perforating artery flow with 2D phase-contrast 7 Tesla MRI at the level of the centrum semiovale (CSO) and the basal ganglia (BG) in seventy participants from the Heart Brain Connection study with carotid occlusive disease (COD), vascular cognitive impairment (VCI), or no actual cerebrovascular disease. Vascular risk factors included hypertension, diabetes, hyperlipidemia, and smoking.

Results: No consistent relations were found between any of the vascular risk factors and either flow velocity or flow pulsatility, although there was a relation between lower diastolic blood pressure and higher pulse pressure and higher cerebral perforator pulsatility (p = 0.045 and p = 0.044, respectively) at the BG level. Results were similar in stratified analyses for patients with and without a history of cardiovascular disease, or only COD or VCI.

Conclusion: We conclude that, cross-sectionally, cerebral perforating artery flow velocity and pulsatility are largely independent of the presence of common vascular risk factors in a population with a mixed vascular burden.

Introduction: Cerebral perforating arteries provide blood supply to the deep regions of the brain. Recently, it became possible to measure blood flow velocity and pulsatility in these small arteries. It is unknown if vascular risk factors are related to these measures.

Methods: We measured perforating artery flow with 2D phase-contrast 7 Tesla MRI at the level of the centrum semiovale (CSO) and the basal ganglia (BG) in seventy participants from the Heart Brain Connection study with carotid occlusive disease (COD), vascular cognitive impairment (VCI), or no actual cerebrovascular disease. Vascular risk factors included hypertension, diabetes, hyperlipidemia, and smoking.

Results: No consistent relations were found between any of the vascular risk factors and either flow velocity or flow pulsatility, although there was a relation between lower diastolic blood pressure and higher pulse pressure and higher cerebral perforator pulsatility (p = 0.045 and p = 0.044, respectively) at the BG level. Results were similar in stratified analyses for patients with and without a history of cardiovascular disease, or only COD or VCI.

Conclusion: We conclude that, cross-sectionally, cerebral perforating artery flow velocity and pulsatility are largely independent of the presence of common vascular risk factors in a population with a mixed vascular burden.

简介大脑穿孔动脉为大脑深部区域提供血液供应。最近,测量这些小动脉的血流速度和搏动性成为可能。目前还不清楚血管风险因素是否与这些测量值有关:我们用二维相衬7特斯拉核磁共振成像测量了心脑连接研究中70名患有颈动脉闭塞性疾病(COD)、血管性认知障碍(VCI)或无实际脑血管疾病的参与者的半脑中心(CSO)和基底节(BG)水平的穿孔动脉血流。血管风险因素包括高血压、糖尿病、高脂血症和吸烟:尽管在 BG 水平上,舒张压较低、脉压较高和大脑穿孔器搏动率较高之间存在关系(分别为 p=0,045 和 p=0,044),但没有发现任何血管风险因素与流速或血流搏动率之间存在一致的关系。对有和无心血管疾病史、仅有COD或VCI的患者进行分层分析,结果相似:我们得出的结论是,从横截面来看,在混合血管负担的人群中,脑穿孔动脉流速和搏动性在很大程度上与是否存在常见血管风险因素无关。
{"title":"The Relation between Vascular Risk Factors and Flow in Cerebral Perforating Arteries: A 7 Tesla MRI Study.","authors":"Laurien Onkenhout, Tine Arts, Doeschka Ferro, Sanne Kuipers, Eline Oudeman, Thijs van Harten, Matthias J P van Osch, Jaco Zwanenburg, Jeroen Hendrikse, Geert Jan Biessels, L Jaap Kappelle","doi":"10.1159/000537709","DOIUrl":"10.1159/000537709","url":null,"abstract":"<p><strong>Introduction: </strong>Cerebral perforating arteries provide blood supply to the deep regions of the brain. Recently, it became possible to measure blood flow velocity and pulsatility in these small arteries. It is unknown if vascular risk factors are related to these measures.</p><p><strong>Methods: </strong>We measured perforating artery flow with 2D phase-contrast 7 Tesla MRI at the level of the centrum semiovale (CSO) and the basal ganglia (BG) in seventy participants from the Heart Brain Connection study with carotid occlusive disease (COD), vascular cognitive impairment (VCI), or no actual cerebrovascular disease. Vascular risk factors included hypertension, diabetes, hyperlipidemia, and smoking.</p><p><strong>Results: </strong>No consistent relations were found between any of the vascular risk factors and either flow velocity or flow pulsatility, although there was a relation between lower diastolic blood pressure and higher pulse pressure and higher cerebral perforator pulsatility (p = 0.045 and p = 0.044, respectively) at the BG level. Results were similar in stratified analyses for patients with and without a history of cardiovascular disease, or only COD or VCI.</p><p><strong>Conclusion: </strong>We conclude that, cross-sectionally, cerebral perforating artery flow velocity and pulsatility are largely independent of the presence of common vascular risk factors in a population with a mixed vascular burden.</p><p><strong>Introduction: </strong>Cerebral perforating arteries provide blood supply to the deep regions of the brain. Recently, it became possible to measure blood flow velocity and pulsatility in these small arteries. It is unknown if vascular risk factors are related to these measures.</p><p><strong>Methods: </strong>We measured perforating artery flow with 2D phase-contrast 7 Tesla MRI at the level of the centrum semiovale (CSO) and the basal ganglia (BG) in seventy participants from the Heart Brain Connection study with carotid occlusive disease (COD), vascular cognitive impairment (VCI), or no actual cerebrovascular disease. Vascular risk factors included hypertension, diabetes, hyperlipidemia, and smoking.</p><p><strong>Results: </strong>No consistent relations were found between any of the vascular risk factors and either flow velocity or flow pulsatility, although there was a relation between lower diastolic blood pressure and higher pulse pressure and higher cerebral perforator pulsatility (p = 0.045 and p = 0.044, respectively) at the BG level. Results were similar in stratified analyses for patients with and without a history of cardiovascular disease, or only COD or VCI.</p><p><strong>Conclusion: </strong>We conclude that, cross-sectionally, cerebral perforating artery flow velocity and pulsatility are largely independent of the presence of common vascular risk factors in a population with a mixed vascular burden.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"121-128"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139717327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cerebrovascular Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1